Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT06022224

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study To Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of a 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

Sponsor: ImmunityBio, Inc.

Conditions COVID-19

Interventions Placebo (0.9% (w/v) saline) hAd5-S-Fusion+N-ETSD

Updated 3 times since 2023 Last updated: Jun 5, 2024 Started: Dec 9, 2020 Primary completion: Jun 23, 2022 Completion: Jul 19, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

There were no participants enrolled into Phase 3 portion of the study because the study was prematurely terminated.

Other terminated trials from ImmunityBio, Inc.

More terminations from ImmunityBio, Inc.

Other COVID-19 trials with similar outcome

Browse all COVID-19 trials

This PHASE2/PHASE3 trial investigates COVID-19 and is currently terminated or withdrawn. ImmunityBio, Inc. leads this study, which shows 3 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Status: Completed → Terminated · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ImmunityBio, Inc.

Data source: ImmunityBio, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Newport Beach, United States